January 2012
The Sanaria®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Press Release). The VRC investigators are recruiting additional volunteers for the study (contact NIAID here and ask to participate in the Sanaria®PfSPZ Vaccine study)
October 2011
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
September 2011
Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity,; Sanaria Press Release, Background, FAQs, Author Bios, Navy Press Release, NIH/NIAID Press Release, UMB Press Release
June 2011
Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology; Press Release
April 2011
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, were nominated as one of the Tech Council of Maryland's three finalists for the 2011 Tech Awards for Biotechnology Firm of the Year and Executive of the Year, respectively
March 2011
Sanaria is proud to announce the appointment of Peter F. Billingsley, PhD, Senior Director of Entomology and Quality Systems, to the Editorial Board of the Malaria Journal; more information
December 2010
Bill Shore appeared on Good Morning America to discuss his book The Imaginations of Unreasonable Men: Inspiration, Vision and Purpose in the Quest to End Malaria, featuring Sanaria's CEO Dr. Stephen L. Hoffman and Sanaria Inc.; video
December 2010
Sanaria, in collaboration with the Walter Reed Army Institute of Research and the Center for Disease Control/National Center for Infectious Disease, publish research results in PLoS ONE; Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria
October 2010
Sanaria, in collaboration with the University of Maryland School of Medicine and Protein Potential, LLC, publish clinical trial results in PLoS ONE; Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial
September 2010
Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards; P & B 53
August 2010
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Mental Floss magazine article, The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It; mentalfloss.com
August 2010
Sanaria's Chief Executive and Scientific Officer, Dr. Stephen L. Hoffman won the Daily Record's Innovator of the Year Award; The Daily Record
August 2010
Sanaria recognized by U.S. Representative Chris Van Hollen for using Recovery Act funding to retain employees and continue its focus on developing a malaria vaccine; POLITICO
February 2010
Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine; Press Release
January 2010
Dr. David Dolberg, Sanaria's Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer; more information
January 2010
Sanaria featured in Volume 6, Issue 1, the January cover, of the Human Vaccines Journal